New Novartis announced that the SYS6045 antibody drug conjugate of the holding subsidiary Jushi Biotech has obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and clinical trials will be carried out in the near future. SYS6045 is a monoclonal antibody drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis, and releases toxins to achieve the effect of killing tumor cells. This product is declared as a therapeutic biological product category 1. The approved indication is advanced solid tumors and is expected to be suitable for the treatment of breast cancer, stomach cancer, endometrial cancer, cervical cancer, colorectal cancer, etc. Preclinical studies have shown that SYS6045 has good anti-tumor effects on various types of cancer and has high clinical development value.

New Novartis announced that the SYS6045 antibody drug conjugate of the holding subsidiary Jushi Biotech has obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and clinical trials will be carried out in the near future. SYS6045 is a monoclonal antibody drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis, and releases toxins to achieve the effect of killing tumor cells. This product is declared as a therapeutic biological product category 1. The approved indication is advanced solid tumors and is expected to be suitable for the treatment of breast cancer, stomach cancer, endometrial cancer, cervical cancer, colorectal cancer, etc. Preclinical studies have shown that SYS6045 has good anti-tumor effects on various types of cancer and has high clinical development value.